Maxcyte (MXCT) Raw Materials (2020 - 2026)

Maxcyte (MXCT) has 7 years of Raw Materials data on file, last reported at $3.5 million in Q1 2026.

• Quarterly Raw Materials fell 21.82% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (down 21.82% YoY) and the FY2025 annual result came in at $3.9 million, down 18.08% from the prior year.
• Raw Materials eased to $3.5 million in Q1 2026 per MXCT's latest filing, from $3.9 million in the prior quarter.
• Across five years, Raw Materials topped out at $6.0 million in Q1 2023 and bottomed at $3.5 million in Q1 2026.
• The 5-year median for Raw Materials is $5.2 million (2022), against an average of $4.9 million.
• The widest annual swing landed in 2022, when Raw Materials soared 224.18%; it then slumped 30.53% in 2025.
• Tracing MXCT's Raw Materials over 5 years: stood at $5.7 million in 2022, then increased by 0.76% to $5.7 million in 2023, then decreased by 17.16% to $4.7 million in 2024, then slipped by 18.08% to $3.9 million in 2025, then retreated by 9.6% to $3.5 million in 2026.
• Per Business Quant, the three latest MXCT Raw Materials figures stand at $3.5 million (Q1 2026), $3.9 million (Q4 2025), and $3.9 million (Q3 2025).

Peer Comparison